At Novo Nordisk, our R&D pipeline reflects our long-standing
commitment to driving change to defeat diabetes and other serious
Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, haemophilia, growth disorders and non-alcoholic steatohepatitis (NASH).
Browse our entire R&D pipeline by study phase, or select a specific therapy areas. Click on a candidate to access up-to-date trial information.